Epizyme reports interim Phase II data for tazemetostat in sarcomas

In an abstract released ahead of the American Society of Clinical Oncology meeting in Chicago, Epizyme Inc. (NASDAQ:EPZM) reported interim data from a cohort of 31 evaluable patients with SWI/SNF related matrix associated actin dependent

Read the full 352 word article

User Sign In